Read More

Arcutis Biotherapeutics Says STRATUM Study Met Its Primary Endpoint, With Nearly 80% Of ZORYVE Foam Treated Individuals Reaching Investigator Global Assessment; Also Demonstrated Improvement On All Secondary Endpoints, Including Itch, Scaling And Eryth…

ZORYVE Foam Clinical DataThe approval is supported by positive results from Arcutis' Phase 2 and pivotal Phase 3 trials in seborrheic dermatitis. The STudy of Roflumilast

ARQT

Read More

Bristol Myers Squibb Provides Update On RELATIVITY-123 Trial Evaluating The Fixed-Dose Combination Of Nivolumab And Relatlimab In Patients With Previously Treated Metastatic Microsatellite Stable Colorectal Cancer

Bristol Myers Squibb (NYSE:BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic

BMY

Read More

Cancer Player Aadi Bioscience Downgraded: Analyst Highlights ‘Worse Than Expected’ Response Rates

Friday, Aadi Bioscience Inc (NASDAQ: AADI) released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with 

AADI